Brittany Turner-Ivey1, Ericka L Smith1, Alex C Rutkovsky1, Laura S Spruill1,2, Jamie N Mills1, Stephen P Ethier3. 1. Department of Pathology and Laboratory Medicine, Hollings Cancer Center, Medical University of South Carolina, 68 President St, Charleston, SC, 29425, USA. 2. Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA. 3. Department of Pathology and Laboratory Medicine, Hollings Cancer Center, Medical University of South Carolina, 68 President St, Charleston, SC, 29425, USA. ethier@musc.edu.
Abstract
PURPOSE: NSD3 has been implicated as a candidate driver oncogene from the 8p11-p12 locus, and we have previously published evidence for its amplification and overexpression in human breast cancer. This aim of this study was to further characterize the transforming function of NSD3 in vivo. METHODS: We generated a transgenic mouse model in which NSD3 gene expression was driven by the MMTV promoter and expressed in mammary epithelium of FVB mice. Mammary glands were fixed and whole mounts were stained with carmine to visualize gland structure. Mammary tumors were formalin-fixed, and paraffin embedded (FFPE) tumors were stained with hematoxylin and eosin. RESULTS: Pups born to transgenic females were significantly underdeveloped compared to pups born to WT females due to a lactation defect in transgenic female mice. Whole mount analysis of the mammary glands of transgenic female mice revealed a profound defect in functional differentiation of mammary gland alveoli that resulted in the lactation defect. We followed parous and virgin NSD3 transgenic and control mice to 50 weeks of age and observed that several NSD3 parous females developed mammary tumors. Whole mount analysis of the mammary glands of tumor-bearing mice revealed numerous areas of mammary hyperplasia and ductal dysplasia. Histological analysis showed that mammary tumors were high-grade ductal carcinomas, and lesions present in other mammary glands exhibited features of alveolar hyperplasia, ductal dysplasia, and carcinoma in situ. CONCLUSIONS: Our results are consistent with our previous studies and demonstrate that NSD3 is a transforming breast cancer oncogene.
PURPOSE:NSD3 has been implicated as a candidate driver oncogene from the 8p11-p12 locus, and we have previously published evidence for its amplification and overexpression in humanbreast cancer. This aim of this study was to further characterize the transforming function of NSD3 in vivo. METHODS: We generated a transgenicmouse model in which NSD3 gene expression was driven by the MMTV promoter and expressed in mammary epithelium of FVB mice. Mammary glands were fixed and whole mounts were stained with carmine to visualize gland structure. Mammary tumors were formalin-fixed, and paraffin embedded (FFPE) tumors were stained with hematoxylin and eosin. RESULTS: Pups born to transgenic females were significantly underdeveloped compared to pups born to WT females due to a lactation defect in transgenic female mice. Whole mount analysis of the mammary glands of transgenic female mice revealed a profound defect in functional differentiation of mammary gland alveoli that resulted in the lactation defect. We followed parous and virgin NSD3transgenic and control mice to 50 weeks of age and observed that several NSD3 parous females developed mammary tumors. Whole mount analysis of the mammary glands of tumor-bearing mice revealed numerous areas of mammary hyperplasia and ductal dysplasia. Histological analysis showed that mammary tumors were high-grade ductal carcinomas, and lesions present in other mammary glands exhibited features of alveolar hyperplasia, ductal dysplasia, and carcinoma in situ. CONCLUSIONS: Our results are consistent with our previous studies and demonstrate that NSD3 is a transforming breast cancer oncogene.
Entities:
Keywords:
Amplicon; Breast cancer; ER positive; NSD3; Oncogene; Transgenic mouse model; WHSC1L1
Authors: Fabrice André; Thomas Bachelot; Mario Campone; Florence Dalenc; Jose M Perez-Garcia; Sara A Hurvitz; Nicholas Turner; Hope Rugo; John W Smith; Stephanie Deudon; Michael Shi; Yong Zhang; Andrea Kay; Diana Graus Porta; Alejandro Yovine; José Baselga Journal: Clin Cancer Res Date: 2013-05-08 Impact factor: 12.531
Authors: Megan Cully; Jessica Shiu; Roland P Piekorz; William J Muller; Susan J Done; Tak W Mak Journal: Cancer Res Date: 2005-11-15 Impact factor: 12.701
Authors: Jingqin Luo; Shuzhen Liu; Samuel Leung; Alejandro A Gru; Yu Tao; Jeremy Hoog; Julie Ho; Sherri R Davies; D Craig Allred; Andrea L Salavaggione; Jacqueline Snider; Elaine R Mardis; Torsten O Nielsen; Matthew J Ellis Journal: J Mol Diagn Date: 2017-01 Impact factor: 5.568
Authors: Gang Yuan; Natasha M Flores; Simone Hausmann; Shane M Lofgren; Vladlena Kharchenko; Maria Angulo-Ibanez; Deepanwita Sengupta; Xiaoyin Lu; Iwona Czaban; Dulat Azhibek; Silvestre Vicent; Wolfgang Fischle; Mariusz Jaremko; Bingliang Fang; Ignacio I Wistuba; Katrin F Chua; Jack A Roth; John D Minna; Ning-Yi Shao; Łukasz Jaremko; Pawel K Mazur; Or Gozani Journal: Nature Date: 2021-02-03 Impact factor: 69.504